Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

[powerpress]

Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

[powerpress]

Historically, lung cancer patients with a KRAS mutation, which is the molecular marker that is actually most common in patients with NSCLC (about 20-25%), have not had extremely appealing treatment options.  In fact, the available data has largely led to the conclusion that both chemotherapy and EGFR inhibitor therapy tends to be, if anything, somewhat less effective for people with a KRAS mutation.  Despite some reason for hope in early research with a few novel therapies, there really hasn't been a good alternative that is specifically effective for KRAS mutation-positive patien

Here's the final piece of the webinar with our own Dr. Jared Weiss on Highlights in Lung Cancer from 2011 -- the question and answer session that followed his presentation.  Below is the transcript, figures, and the audio and video versions of the podcast.

Several weeks ago, we were fortunate enough to be joined by not one but two international stars in lung cancer research that is being translated directly from lab bench to bedside of the patient. I don't think there's a more clear and inspiring example of good science leading to effective therapy, albeit for a limited patient population, than the story of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (recently FDA approved and commercially launched as XALKORI) for patients with an EML4-ALK rearrangement (approximately 4% of the broader NSCLC population). Drs.

Continuing Dr. West's theme discussing new therapies for patients with acquired resistance, I'd like to answer a few questions about HSP 90 inhibitors that have caught my attention on GRACE over the past few weeks, and in particular, highlight my "pet" targeted agent, AUY922. HSP 90 inhibitors are drugs that many of you already know about-they are being studied in patients with ALK(+)lung cancer and as a 2^nd line therapy option for all patients with lung cancer with Taxotere.

I've written in the past about a class of proteins known as heat shock protein inhibitors as a targeted anticancer therapy, and there are a few that have been in clinical trials, including IPI-504 from Infinity Pharmaceuticals and STA-9090 from Synta Pharmaceuticals, with others also in development. The only trial that has actually been the subject of a completed clinical trial in NSCLC is IPI-504. Dr.